Legal & General Group PLC Alpine Immune Sciences, Inc. Transaction History

Legal & General Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$17.75 - $41.6 $82,324 - $192,940	4,638 Added 17.66%	30,901 $1.22 Million
Q4 2023 Feb 15, 2024	BUY	$8.54 - $20.22 $30,299 - $71,740	3,548 Added 15.62%	26,263 $500,000
Q3 2023 Nov 14, 2023	BUY	$10.13 - $13.98 $194,728 - $268,737	19,223 Added 550.49%	22,715 $260,000
Q2 2023 Aug 14, 2023	BUY	$6.84 - $11.91 $6,969 - $12,136	1,019 Added 41.21%	3,492 $35,000
Q4 2022 Feb 14, 2023	BUY	$5.45 - $7.35 $5,618 - $7,577	1,031 Added 71.5%	2,473 $18,000
Q2 2022 Aug 22, 2022	BUY	$6.71 - $9.52 $1,442 - $2,046	215 Added 17.52%	1,442 $12,000
Q2 2021 Aug 12, 2021	BUY	$8.81 - $15.03 $10,809 - $18,441	1,227 New	1,227 $11,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.